Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardima CE marks surgical ablation probe for atrial fibrillation

This article was originally published in Clinica

Executive Summary

Cardiology specialist Cardima has CE marked its surgical ablation probe for sale in Europe. The probe is part of the firm's surgical ablation system, which is used to treat atrial fibrillation. The system can be employed in open-chest surgery in combination with other procedures, or alone in less-invasive, closed-chest procedures. During the latter, Cardima's system allows cardiac surgeons to gain access to the heart via "two or three small ports in the chest". The system also treats both the left and right aortas, which Cardima (Fremont, California) believes is necessary for successful treatment. The system is already approved by the US FDA for the ablation of cardiac tissue.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT077109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel